Results 31 to 40 of about 2,485 (155)

Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis

Southern African Journal of HIV Medicine, 2023
The number of products that can provide pre-exposure prophylaxis (PrEP) for HIV prevention is expanding, with three now approved in South Africa (oral Tenofovir-based PrEP, injectable Cabotegravir, and a Dapivirine-based vaginal ring) and more in the ...
Carey Pike, Elzette Rousseau, Linda-Gail Bekker   +2 more
doaj   +1 more source

WHO guidance grounded in a comprehensive approach to sexual and reproductive health and human rights: topical pre-exposure prophylaxis [PDF]

, 2014
Introduction: Two new microbicide products based on topical (vaginal) application of antiretroviral drugs – 1% tenofovir gel and the dapivirine ring – are currently in late-stage clinical testing, and results on their safety and effectiveness are ...
Elizabeth McGrory, Fourth World Conference on Women, Gray, Manjula Lusti-Narasimhan, Marleen Temmerman, Marrazzo, Plan of Action of the International Conference, Rachel Baggaley, Rajat Khosla, The President's Emergency Plan for AIDS Relief, Tim Farley, World Health Organization, World Health Organization, World Health Organization   +13 more
core   +8 more sources

Use of simulated vaginal and menstrual fluids to model in vivo discolouration of silicone elastomer vaginal rings

International Journal of Pharmaceutics: X, 2021
Vaginal rings releasing antiretrovirals – either alone or in combination with contraceptive progestins – are being developed for prevention of human immunodeficiency virus (HIV) transmission via vaginal sex.
Clare F. McCoy, Patrick Spence, Yahya H. Dallal Bashi, Diarmaid J. Murphy, Peter Boyd, Bindi Dangi, Tiffany Derrick, Bríd Devlin, Kyle Kleinbeck, R. Karl Malcolm   +9 more
doaj   +1 more source

Multipurpose vaginal rings for HIV prevention and non-hormonal contraception

British Journal of Pharmacy, 2022
Vaginal rings releasing antiretrovirals - either alone or in combination with contraceptive progestins - are being developed for contraception and prevention of human immunodeficiency virus (HIV) transmission via vagina.
Xin Shen, Peter Boyd, Yahya Dallal Bashi, Clare McCoy , Karl Malcolm   +4 more
doaj   +1 more source

Development of Mucoadhesive Gel Microbicide to Target Mucosal HIV Reservoirs [PDF]

, 2014
The wide use of microbicide is mainly depends on its effectiveness, less frequent application, ready availability and most importantly cost. The aim of this work was to develop affordable microbicide mucoadhesive gel formulation of synthetic anti HIV ...
Shegokar, Ranjita, Singh, Kamalinder K
core   +1 more source

Inhibition of HIV virus by neutralizing Vhh attached to dual functional liposomes encapsulating dapivirine [PDF]

, 2016
Although highly active antiretroviral therapy (HAART) has greatly improved the life expectancy of HIV/AIDS patients, the treatment is not curative.
AF Labrijn, AK Bhatia, BR Starcich, DC Chan, DF Gaddy, DS Watson, E Chertova, EO Freed, G Ofek, GNC Chiu, Guido Vanham, HL Wong, Ivan Roitt, J Cunha Da, J das Neves, J Icenogle, J Liu, Johan Michiels, JP Moore, JS Klein, JS Klein, Kevin K. Ariën, KV1 Rao, L Nieba, LE McCoy, M-Y Zhang, NK Malavia, P Zhu, P Zhu, PD Kwong, PD Kwong, R Clayton, R Duncan, R Wyatt, R Wyatt, RL Shew, Roger New, S Oliveira, Scarlet Xiaoyan Wang, SP Layne, TJ Smith, WWL Koh, X Wei, X Yu   +43 more
core   +4 more sources

Optimization of diarylazines as anti-HIV agents with dramatically [PDF]

, 2013
Non-nucleoside inhibitors of HIV-1 reverse transcriptase are reported that have ca. 100-fold greater solubility than the structurally related drugs etravirine and rilpivirine, while retaining high anti-viral activity.
Anderson, Karen S., Bollini, Mariela, Cisneros, José A., Jorgensen, William L., Spasov, Krasimir A.   +4 more
core   +1 more source

Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrel [PDF]

, 2016
A matrix-type silicone elastomer vaginal ring providing 28-day continuous release of dapivirine (DPV) - a lead candidate human immunodeficiency virus type 1 (HIV-1) microbicide compound - has recently demonstrated moderate levels of protection in two ...
Blanda, Wendy, Boyd, Peter, Brimer, Andrew, Devlin, Brid, Fetherston, Susan M, Holt, Jonathon, Kumar, Sandeep, Major, Ian, Malcolm, R Karl, McCoy, Clare F, Murphy, Diarmaid J   +10 more
core   +1 more source

Review The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors

Viruses, 2014
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs.
Nicolas Sluis-Cremer
doaj   +1 more source

Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.

PLoS ONE, 2016
BackgroundThis was the first microbicide trial conducted in Africa to evaluate an antiretroviral-containing vaginal ring as an HIV prevention technology for women.ObjectivesThe trial assessed and compared the safety, acceptability and adherence to ...
Annalene Nel, Linda-Gail Bekker, Elizabeth Bukusi, Elizabeth Hellstrӧm, Philip Kotze, Philip Kotze, Cheryl Louw, Francis Martinson, Gileard Masenga, Elizabeth Montgomery, Nelisiwe Ndaba, Ariane van der Straten, Neliëtte van Niekerk, Cynthia Woodsong   +13 more
doaj   +1 more source